REC, interventional cardiology · 2025
VerifyNow in acute coronary syndrome: design of the EPIC17-VERONICA trial to optimize platelet inhibition.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Garilleti Cámara Celia, de la Torre-Hernández José María, Rumoroso Cuevas José Ramón, Romaní Sebastián, Monastyrski Andrea Virginia, Nieto Alejandro Diego, Bayón Lorenzo Jeremías, Cubero Gallego Héctor, Gómez-Hospital Joan Antoni, Vallejo Calcerrada Nuria, Pérez Guerrero Ainhoa, Amat-Santos Ignacio J, Alcalde Martínez Vicente, López-Palop Ramón, Jimeno Sánchez Javier, Pérez de Prado Armando, Lozano Martínez-Luengas Íñigo
Аннотация
INTRODUCTION AND OBJECTIVES: De-escalation from prasugrel and ticagrelor to clopidogrel in patients undergoing percutaneous coronary intervention after acute coronary syndrome (ACS) is a strategy aimed at reducing bleeding. This study evaluates whether VerifyNow (Werfen, Spain)-guided de-escalation, based on platelet aggregation measurement, provides a therapeutic benefit in ACS management.
METHODS: This ongoing multicenter, prospective, randomized 1:1 trial will enroll 634 patients with ACS who underwent revascularization with a sirolimus-eluting stent and were discharged on dual antiplatelet therapy with ticagrelor or prasugrel. Only those patients with a very low platelet reactivity level (platelet reactivity units ≤ 30) based on VerifyNow 1 month after discharge will be included. The primary endpoint is a composite of cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, and bleeding at 1-year follow-up.
RESULTS: The EPIC17-VERONICA study (NCT04654052) will reveal the efficacy profile of the de-escalation strategy, based on the VerifyNow platelet aggregation test, and determine the role of this device in the selection of patients who are eligible to benefit from this strategy.
CONCLUSIONS: This study will determine whether platelet function testing provide clinical benefit in the management of patients with ACS.
METHODS: This ongoing multicenter, prospective, randomized 1:1 trial will enroll 634 patients with ACS who underwent revascularization with a sirolimus-eluting stent and were discharged on dual antiplatelet therapy with ticagrelor or prasugrel. Only those patients with a very low platelet reactivity level (platelet reactivity units ≤ 30) based on VerifyNow 1 month after discharge will be included. The primary endpoint is a composite of cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, and bleeding at 1-year follow-up.
RESULTS: The EPIC17-VERONICA study (NCT04654052) will reveal the efficacy profile of the de-escalation strategy, based on the VerifyNow platelet aggregation test, and determine the role of this device in the selection of patients who are eligible to benefit from this strategy.
CONCLUSIONS: This study will determine whether platelet function testing provide clinical benefit in the management of patients with ACS.